Disc Medicine's DISC-0974 shows positive results in treating anemia of myelofibrosis.

Disc Medicine has presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF. The trial showed substantial reductions in hepcidin and increases in iron levels, resulting in positive impacts on clinically meaningful measures of anemia across various patient subgroups. Treatment was also seen to be effective regardless of concomitant JAK inhibitor therapy use.